Bioxel signs new paclitaxel purchase agreement with European Union generic manufacturer

By E. Janene Geiss

Philadelphia, Dec. 9 - Bioxel Pharma Inc. announced Friday that it has completed a purchase agreement with a new European generic manufacturer.

Bioxel's client is already marketing its generic paclitaxel formulation in several European Union countries and intends to obtain approvals throughout Europe in 2006, according to a company news release.

To respect confidentiality, the generic manufacturer and the specific terms of the transaction have not been disclosed, officials said.

"The EU market push that we started in the first quarter is paying off," Pascal Delmas, president and chief executive officer, said in the release.

"This is the third significant transaction for Bioxel in Europe this year. These commercial successes demonstrate the competitiveness, quality and reliability of our products," he added.

The company said it will continue to focus on the EU market, where it anticipates securing paclitaxel supply agreements soon.

Bioxel, based in Sainte-Foy, Quebec, manufactures and sells cGMP paclitaxel to specialty pharmaceutical companies and generic formulation manufacturers. The company's dedicated cGMP paclitaxel facility has a 120 kilogram annual manufacturing capacity. It is located at an FDA-inspected pharmaceutical manufacturing site. Bioxel's paclitaxel is registered with U.S., E.U. and Canadian regulatory authorities, allowing its use worldwide, official said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.